CEP192

Across TCGA pan-cancer cohorts, CEP192 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CEP192 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uveal melanoma (UVM), where higher CEP192 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CEP192 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

UVM, UCEC, and LUSC are the cancer types where CEP192 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	OS	Median	All	0.104	0.858	<.001	33	view →
UCEC	DFS	Median	II,III,IV	0.912	0.424	.004	22	view →
LUSC	DFS	Median	II,III,IV	0.079	0.750	<.001	17	view →
CESC	DFS	Median	III,IV	0.240	0.726	.015	6	view →
PRAD	DFS	Median	All	0.087	0.777	<.001	6	view →
COAD	OS	Median	II,III,IV	1.000	0.772	.033	2	view →
SKCM	OS	Median	All	0.660	0.874	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CEP192–UVM (OS)

Open the UVM breakdown →